-
2023-505980-36-00
5
2019-09-19
Primary progressive multiple sclerosis (PPMS)
-
2023-505321-14-00
10
2019-09-06
Warm Autoimmune Hemolytic Anemia
-
2023-509605-77-00
1
2019-06-27
Advanced solid tumours
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2024-516479-34-00
5
2019-05-17
Hepatocellular carcinoma
-
2024-519288-17-00
4
2019-04-26
High-risk Non-muscle Invasive Bladder Cancer
-
2023-509349-11-00
5
2019-03-22
Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or
-
2023-507564-39-00
1
2019-03-11
Patients with Advanced Solid Tumors
-
2024-513867-19-00
5
2019-01-31
metastatic Castration-Resistant Prostate Cancer (mCRPC)
-
2023-507906-15-00
5
2019-01-30
Relapsing multiple sclerosis (RMS)
-
2024-513912-89-00
10
2018-12-13
Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
-
2024-516662-11-00
5
2018-11-23
Ovarian epithelial
cancer
-
2023-506994-36-00
5
2018-10-11
Ulcerative Colitis
-
2024-510967-41-00
5
2018-09-21
Metastatic colorectal cancer
-
2023-508018-41-00
4
2018-07-27
Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential
-
2023-509976-40-00
5
2018-05-28
Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
2023-507500-31-00
10
2017-08-22
Advanced or metastatic Non-small cell lung cancer (NSCLC)
-
2023-509354-58-00
5
2017-07-14
Mantle Cell Lymphoma
-
2024-511348-25-00
10
2015-12-11
Myelodysplastic syndromes (MDS)
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2023-506524-82-00
5
2015-10-21
Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirme
-
2023-509348-84-00
5
2015-04-27
Chronic Lymphocytic Leukemia
-
2024-512243-23-00
5
2014-11-07
gastrointestinal stromal tumor
-
2024-518951-52-00
4
2025-11-12
Worsening Heart Failure